Korean J Intern Med.
2017 May;32(3):497-504. 10.3904/kjim.2015.404.
Effects of valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension: a randomized, multicenter study
- Affiliations
-
- 1Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea. lkw65@ajou.ac.kr
- 2Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
- 3Department of Internal Medicine, Daejin Medical Center, Bundang Jesaeng Hospital, Seongnam, Korea.
- 4Department of Internal Medicine, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, Korea.
- 5Department of Internal Medicine, Seoul Medical Center, Seoul, Korea.
- 6Department of Internal Medicine, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea.
- 7Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea.
- 8Department of Internal Medicine, Wonkwang University Sanbon Hospital, Gunpo, Korea.
- KMID: 2379480
- DOI: http://doi.org/10.3904/kjim.2015.404
Abstract
- BACKGROUND/AIMS
Oxidative stress plays an important role in the pathogenesis and progression of diabetic complications and antagonists of renin-angiotensin system and amlodipine have been reported previously to reduce oxidative stress. In this study, we compared the changes in oxidative stress markers after valsartan and amlodipine treatment in type 2 diabetic patients with hypertension and compared the changes in metabolic parameters.
METHODS
Type 2 diabetic subjects with hypertension 30 to 80 years of age who were not taking antihypertensive drugs were randomized into either valsartan (n = 33) or amlodipine (n = 35) groups and treated for 24 weeks. We measured serum nitrotyrosine levels as an oxidative stress marker. Metabolic parameters including serum glucose, insulin, lipid profile, and urine albumin and creatinine were also measured.
RESULTS
After 24 weeks of valsartan or amlodipine treatment, systolic and diastolic blood pressure decreased, with no significant difference between the groups. Both groups showed a decrease in serum nitrotyrosine (7.74 ± 7.30 nmol/L vs. 3.95 ± 4.07 nmol/L in the valsartan group and 8.37 ± 8.75 nmol/L vs. 2.68 ± 2.23 nmol/L in the amlodipine group) with no significant difference between the groups. Other parameters including glucose, lipid profile, albumin-to-creatinine ratio, and homeostasis model assessment of insulin resistance showed no significant differences before and after treatment in either group.
CONCLUSIONS
Valsartan and amlodipine reduced the oxidative stress marker in type 2 diabetic patients with hypertension.
MeSH Terms
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Addition of Amlodipine or Valsartan for Improvement of Diastolic Dysfunction Associated with Hypertension
- Valsartan 160 mg/Amlodipine 5 mg Combination Therapy versus Amlodipine 10 mg in Hypertensive Patients with Inadequate Response to Amlodipine 5 mg Monotherapy
- Chlorthalidone, not hydrochlorothiazide, is the right diuretic for comparison
- Protective Effects of Lithospermic Acid B on Diabetic Nephropathy in OLETF Rats Comparing with Amlodipine and Losartan
- Amlodipine monotherapy in patients with essential hypertension
